NCT01542541View on ClinicalTrials.gov

A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans

NACompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Intestinal FDG Uptake
Interventions
DRUG

Rifaximin

550mg BID for 2 days

Trial Locations (1)

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

Bausch Health Americas, Inc.

INDUSTRY

lead

Beth Israel Deaconess Medical Center

OTHER

NCT01542541 - A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans | Biotech Hunter | Biotech Hunter